Trial Title:
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
NCT ID:
NCT06461988
Condition:
Multiple Myeloma
Post Stem Cell Transplant
Conditions: Official terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Lenalidomide
Conditions: Keywords:
Talequetamab
Lenalidomide
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Talquetamab
Description:
Talquetamab Step up dosing:
C1D1: 10 mcg/kg C1D3a: 60 mcg/kg C1D5a: 400 mcg/kg C1D15: 800 mcg/kg
Talquetamab 800 mg/kg SC Q4W in 28-day cycle for Cycles 2-13
Arm group label:
Talquetamab
Intervention type:
Drug
Intervention name:
Talquetamab and Lenalidomide
Description:
Lenalidomide 10 mg, 3 weeks on 1 week off, until PD/ intolerance, C2-13 (Lenalidomide 5
mg for creatinine clearance 30-60 ml/min)
Arm group label:
Talquetamab
Summary:
Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal
proliferation of plasma cells and organ damage. Autologous transplantation with high dose
chemotherapy is the standard of care in frontline treatment of eligible patients with MM.
Detailed description:
This is a phase 2 study to evaluate the efficacy of talquetamab with a combination of
lenalidomide, and to determine the safety and longitudinal patient reported symptoms and
quality of life.
Thirty participants with MM who plan to undergo or who have undergone autologous stem
cell transplant as a part of their initial therapy and meet the eligibility criteria will
be enrolled in the study.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Participants must have had a confirmed diagnosis of symptomatic multiple myeloma
according to according to IMWG diagnostic criteria.
2. Measurable disease at the time of myeloma diagnosis Measurable disease is defined as
measurable M protein in the serum (≥ 0.5g/dL) or urine (≥ 200 mg/24h) or serum free
light chain assay (defined as dFLC ≥ 10 mg/dL [≥ 100 mg/L]; difference between
involved and uninvolved free light chain) at the time of diagnosis. Participants
with smoldering myeloma are not eligible until they have progressed to symptomatic
myeloma. Participants with purely non-secretory MM at the time of diagnosis as
measured by electrophoresis and immunofixation and the absence of Bence Jones
proteins in the urine are not eligible.
3. Age >18 years.
4. Patients who have already received transplant should have undergone autologous stem
cell transplant with Melphalan 140 mg/m2 within 12 months of start of induction
therapy of multiple myeloma and are within day +60-120 post-transplant. Patients who
have not already received transplant must have begun induction therapy within 12
months prior to the planned date of transplant.
5. Participants must not be refractory to lenalidomide
6. Participants must not have progressive disease at any time prior to registration
7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
8. Have clinical laboratory values meeting the following criteria during the Screening
Phase and also at start of administration of study treatment:
- Hemoglobin: ≥ 8 g/dL (≥ 4.96 mmol/L; without transfusion support or
erythropoietin use within 7 days before the laboratory test)
- Platelets: ≥ 75×109/L in participants in whom <50% of bone marrow nucleated
cells are plasma cells and ≥ 50×109/L in participants in whom ≥50% of bone
marrow nucleated cells are plasma cells (without transfusion support or
thrombopoietin receptor agonist within 7 days before the laboratory test)
- Absolute neutrophil count: ≥ 1.0×109/L (prior growth factor support is
permitted but must be without support for 7 days for G-CSF or GM-CSF and for 14
days for pegylated GCSF before the laboratory test)
- AST and ALT: ≤2.5×ULN
- Creatinine clearance: ≥30 mL/min based on Cockcroft Gault equation
- Total bilirubin: ≤2.0×ULN; except in participants with congenital
bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin
≤1.5×ULN is required)
- Serum calcium corrected for albumin: ≤14 mg/dL (≤3.5 mmol/L) or free ionized
calcium ≤6.5 mg/dL
(ALT=alanine aminotransferase; AST=aspartate aminotransferase; GCSF=granulocyte
colony stimulating factor; GM-CSF=granulocyte-macrophage colony stimulating factor;
RBC=red blood cell; ULN=upper limit of normal)
9. A woman of childbearing potential must have a negative highly sensitive urine or
serum (β human chorionic gonadotropin [β hCG]) pregnancy test at screening, again a
negative serum test within 48 hours prior to the start of study treatment.
10. A woman must be:
1. Not of childbearing potential, or
2. Of childbearing potential and
1) Practicing true abstinence; or 2) Have a sole partner who is bilaterally
vasectomized; or 3) Practicing 2 effective methods of contraception (at
least 1 highly-effective, method of contraception (see 3 for methods of
contraception allowed).
NOTE: Participant must agree to continue the above throughout the study and for 100
days after the last dose of study treatment.
NOTE: If a woman becomes of childbearing potential after start of the study the
woman must comply with point (b) as described above. If a participant's reproductive
status is questionable, additional evaluation should be considered.
NOTE: An interaction between hormonal contraception and talquetamab has not been
formally studied. Therefore, it is unknown whether talquetamab may reduce the
efficacy of the contraception method. If a woman is receiving talquetamab and is
using hormonal contraceptives, an additional barrier method must be used.
NOTE: Sexual abstinence is considered a highly effective method only if defined as
refraining from heterosexual intercourse during the entire period of risk associated
with the study treatment. The reliability of sexual abstinence needs to be evaluated
in relation to the duration of the study and the preferred and usual lifestyle of
the participant.
11. A woman must agree not to donate eggs (ova, oocytes) or freeze for future use, for
the purposes of assisted reproduction during the study and for 100 days after
receiving the last dose of study treatment
12. A man must wear a condom (with spermicidal foam/gel/film/cream/suppository) when
engaging in any activity that allows for passage of ejaculate to another person
during the study and for a minimum of 100 days after receiving the last dose of
study treatment. If a female partner is of childbearing potential, she must also be
practicing a highly effective method of contraception (see Section 13.2, Appendix
2).
NOTE: If the male participant is vasectomized, he still must wear a condom (with
foam/gel/film/cream/suppository), but his female partner is not required to use
contraception.
13. A male participant must agree not to donate sperm for the purpose of reproduction
during the study and for a minimum of 100 days after receiving the last dose of
study treatment.
14. Must be willing and able to adhere to the lifestyle restrictions specified in this
protocol ( Section 3.2), including to not donate blood or blood components during
the study and for 100 days after the last dose of study drug). This includes
complying with REMS program for lenalidomide. Per lenalidomide REMS program. In
women of childbearing potential, pregnancy testing is needed weekly during the first
month of treatment with lenalidomide, then monthly thereafter in females with
regular menstrual cycles or every 2 weeks in females with irregular menstrual
cycles.
15. Must sign an ICF (or their legally acceptable representative must sign) indicating
that the participant understands the purpose of, and procedures required for, the
study and is willing to participate in the study.
16. Willingness to return to study site for follow-up
Exclusion Criteria:
1. Intolerance to lenalidomide 10 mg (or 5 mg for patients with creatinine clearance
30-60 ml/min).
2. Refractory or relapsed multiple myeloma at any time before enrollment
3. Contraindications or life-threatening allergies, hypersensitivity, or intolerance to
any study drug or its excipients (refer to the talquetamab Investigator's Brochure
and appropriate package inserts).
4. Prior or concurrent exposure to any of the following, in the specified time frame as
defined below:
a. Received any prior GRPRCD5-directed therapy b. Received prior T-cell redirection
therapy (for example, antibody therapy or BiTE's) or Chimeric antigen T cell
therapy. Gene-modified adoptive cell therapy (eg, chimeric antigen receptor modified
T cells, NK cells) within 3 months c. Targeted therapy, epigenetic therapy, or
treatment with an investigational drug or an invasive investigational medical device
within 21 days or ≥5 half-lives, whichever is less d. Investigational vaccine other
than SARS CoV-2 vaccine approved/ in use under emergency approval within 4 weeks e.
Live, attenuated vaccine within 4 weeks. f. Monoclonal antibody therapy within 21
days g. Cytotoxic therapy within 21 days h. PI therapy within 14 days i. IMiD agent
therapy within 14 days j. Radiotherapy within 14 days or focal radiation within 7
days
5. A maximum cumulative dose of corticosteroids of ≥ 140 mg of prednisone or equivalent
within 14-day period before the first dose of study drug (does not include
pretreatment medications) (Section 13.8, Appendix 8)
6. Known active CNS involvement or exhibits clinical signs of meningeal involvement of
multiple myeloma. If either is suspected, negative whole brain MRI and lumbar
cytology are required.
7. Plasma cell leukemia at the time of screening, Waldenström's macroglobulinemia,
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin
changes), or primary amyloid light chain amyloidosis.
8. Myelodysplastic syndrome or active malignancies (ie, progressing or requiring
treatment change in the last 24 months) other than relapsed/refractory multiple
myeloma. The only allowed exceptions are:
1. Non-muscle invasive bladder cancer treated within the last 24 months that is
considered completely cured
2. Skin cancer (non-melanoma or melanoma) treated within the last 24 months that
is considered completely cured.
3. Noninvasive cervical cancer treated within the last 24 months that is
considered completely cured
4. Localized prostate cancer (N0M0):
1. With a Gleason score of ≤6, treated within the last 24 months, or untreated and
under surveillance 2. With a Gleason score of 3+4 that has been treated >6 months
prior to full study screening and considered to have a very low risk of recurrence,
or e). History of localized prostate cancer and receiving androgen deprivation
therapy and considered to have a very low risk of recurrence.
f) Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in
situ, or history of localized breast cancer and receiving antihormonal agents and
considered to have a very low risk of recurrence g) Other malignancy that is considered
cured with minimal risk of recurrence.
9. Stroke or seizure within 6 months prior to signing ICF.
10. Participant is pregnant, breast-feeding, or planning to become pregnant while
enrolled in this study or within 100 days after the last dose of study treatment.
11. Participant plans to father a child while enrolled in this study or within 100 days
after the last dose of study treatment.
12. Presence of the following cardiac conditions:
a) New York Heart Association stage III or IV congestive heart failure b) Myocardial
infarction or coronary artery bypass graft ≤6 months prior to randomization c)
Uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities d) History of
clinically significant ventricular arrhythmia or unexplained syncope, not believed to be
vasovagal in nature or due to dehydration e) History of severe non-ischemic
cardiomyopathy
13. Any of the following:
a. Known to be seropositive for human immunodeficiency virus
1. Active hepatitis B infection (ie, HBsAg or HBV-DNA positive). In the event the
infection status is unclear, quantitative viral levels are necessary to determine
the infection status see Section 0 for further required assessments.
2. Active hepatitis C infection as measured by positive HCV-RNA testing. Participants
with a history of HCV antibody positivity must undergo HCV-RNA testing. If a
participant with history of chronic hepatitis C infection (defined as both HCV
antibody and HCV-RNA positive) completed antiviral therapy and has undetectable
HCV-RNA for at least 12 weeks following the completion of therapy, the participant
is eligible for the study.
14. Major surgery within 2 weeks prior to the start of administration of study
treatment, or will not have fully recovered from surgery, or has major surgery
planned during the time the participant is expected to be treated in the study
or within 2 weeks after administration of the last dose of study treatment.
NOTE: Participants with planned surgical procedures to be conducted under local
anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major
surgery. If there is a question whether a procedure is considered a major surgery, the
investigator must consult with the study principal investigator and resolve any issues
before enrolling a participant in the study.
15. Concurrent medical or psychiatric condition or disease that is likely to interfere
with study procedures or results, or that in the opinion of the investigator would
constitute a hazard for participating in this study, such as:
1. Uncontrolled diabetes
2. Acute diffuse infiltrative pulmonary disease
3. Evidence of active systemic viral, fungal, or bacterial infection, requiring
systemic antimicrobial therapy
4. Active autoimmune disease requiring systemic immunosuppressive therapy within 6
months before start of study treatment. EXCEPTION: Participants with vitiligo,
controlled type I diabetes, and prior autoimmune thyroiditis that is currently
euthyroid based on clinical symptoms and laboratory testing are eligible regardless
of when these conditions were diagnosed.
5. Disabling psychiatric conditions (e.g., alcohol or drug abuse), severe dementia, or
altered mental status
6. Any other issue that would impair the ability of the participant to receive or
tolerate the planned treatment at the investigational site, to understand informed
consent or any condition for which, in the opinion of the investigator,
participation would not be in the best interest of the participant (e.g., compromise
the well-being) or that could prevent, limit, or confound the protocol-specified
assessments
All subject files must include supporting documentation to confirm subject eligibility.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Stanford University
Address:
City:
Palo Alto
Zip:
94304
Country:
United States
Contact:
Last name:
Kelly Chyan
Facility:
Name:
New Mexico Cancer Research Alliance
Address:
City:
Albuquerque
Zip:
87102
Country:
United States
Start date:
November 2024
Completion date:
June 2026
Lead sponsor:
Agency:
Stanford University
Agency class:
Other
Collaborator:
Agency:
Janssen Scientific Affairs, LLC
Agency class:
Industry
Source:
Stanford University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06461988
